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Letters to the Editor
Antiviral therapy preceding liver transplantation in HCV cirrhosis –
Still too many doubts
To the Editor:
Carrion et al. [1] suggested that antiviral therapy in pa-
tientswithHCV cirrhosis before liver transplantationwas
quite successful in terms of virological response, and may
prevent a recurrence of HCV infection in the graft. How-
ever, it should be underlined that the authors used only
surrogate endpoints. The main hard endpoint, which is
death of the patient, was omitted in the discussion. On
the intention-to-treat basis, in the treated group the pre-
transplant mortality was fourfold higher compared to
the untreated group (4 vs. 1). The lack of statistical signif-
icance is secondary to the small number of patients in both
groups, but who can state it would still be observed if the
groups were more numerous? Additionally, it should be
mentioned that 4 other patients in the treated group were
excluded from the waiting list, which means that they
most probably also died, compared to none in the un-
treated group. Moreover, antiviral treatment prior to li-
ver transplantation in the HCV-infected patients was
previously reported to be connected to more frequent
and earlier recurrence in the transplant, and with in-
creased post-transplant mortality, compared to the un-
treated group [2]. Therefore, in our opinion, the risk of
pre-transplant anti-HCV therapy in cirrhotic patients is
not limited to bacterial infections and myelotoxicity, but
is muchmore complex. In summary, liver transplantation
is a life-saving procedure and mortality, as the hard end-
point, should never be omitted in such analyses. The ran-
domized clinical studies including large number of
patients and long-term post-transplant follow-up should
be performed to enable valuable conclusions concerning
eﬃcacy and safety of antiviral therapy preceding liver
transplantation in HCV cirrhotic patients.
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Journal of Hepatology 51 (2009) 960–966Antiviral therapy in HCV-infected cirrhotic patients awaiting
liver transplantationTo the Editor:
We would like to thank Niemczyk et al. [1] for read-
ing our manuscript [2] and taking the time to make some
comments. We would like, however, to clarify some of
the criticisms they made:1. First, contrary to what was claimed we did not
omit the survival endpoint in the manuscript. In fact,
in the Results section of the paper [2] we clearly state
that 5 patients died before LT (4 from the treated group,
1 from the control group) and that 2 from the treated
HCV infected patients awaiting LT-
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Fig. 1. Proposed algorithm for antiviral treatment in HCV-infected patients awaiting liver transplantation (LT). Good virological proﬁle: infection with
genotype 2 or 3, or infection with genotype 1 and low viral load. SBP: spontaneous bacterial peritonitis.
Letters to the Editor / Journal of Hepatology 51 (2009) 960–966 961group died because of a severe infection. We clearly state
that ‘‘diﬀerences in survival before LT may not have
reached statistical signiﬁcance due to the small size of
the cohort” (p. 723). Probably, the authors of the letter
missed this paragraph when reading the paper. Since the
number of events (deaths) is small, we cannot make a
strong case on this issue. In any case mortality needs
to be analyzed not only before transplantation but also
after LT, particularly due to the fact that hepatitis C
recurrence is the ﬁrst cause of graft (and patient) loss
in a signiﬁcant number of liver transplant programs
[3,4].
2. We believe that we have been very cautious
when making recommendations based on our results.
In fact, since severe infections occurred in patients
with advanced liver failure (Child C), we stated that
‘‘antiviral treatment should not be recommended in
patients with a baseline Child–Pugh >9 or MELD
>18” (p. 727).
3. Exclusion of 4 patients from the treated group was
not owing to death, as the authors suggest. Patients did
not undergo liver transplantation due to central pontine
myelinolysis (1 patient), lack of family support (1 pa-
tient) and progression of hepatocellular carcinoma (2
patients) while awaiting liver transplantation.
4. The authors state that treatment with interferon
before transplantation may be detrimental and increase
the severity of hepatitis C recurrence after LT. They
based this statement citing an abstract (which by the
way is already published as a full paper [5]). If the
authors read the manuscript carefully, they will realize
that in the referred study, any previous exposure to
interferon was considered as treatment, and thus, these
were not patients treated while awaiting LT. In our
experience, based on treatment of approximately 90 pa-
tients while awaiting LT, we did not observe any diﬀer-
ences in the severity of hepatitis C recurrence between
non-responders and patients who did not undergo anti-
viral therapy in the waiting list (unpublished data). We
would like to add two more comments regarding this
point: (a) there are no solid data in the literature sug-
gesting changes in the outcome of hepatitis C recurrence
in patients treated with interferon-based regimens while
awaiting LT; (b) currently, most patients undergo inter-
feron (and ribavirin) treatment at some point during the
course of their disease and, with the use of more eﬃcient
treatment regimens, this proportion will increase in the
future. Refraining from treating patients who have a
reasonable chance to clear HCV based on unsustained
observations is not acceptable.
5. It is obvious that a randomized controlled study
would be the best approach to validate the results that
we (and others [2,6,7]) have published. Regretfully, the
design of such a study is very diﬃcult and should involve
many experienced centers. It is possible that the use of
speciﬁcally targeted therapy for HCV will soon be a
choice for patients with advanced liver disease. Mean-
while, our algorithm to decide treatment of patients
awaiting LT is shown above (Fig. 1).
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of liver disease matter?
To the Editor:
We read with great interest the paper by Kadayifci
et al. [1] regarding the prevalence of coronary artery dis-
ease (CAD) and risk factors for atherosclerosis in liver
cirrhosis. The authors reviewed retrospectively the pa-
tient notes of 60 subjects with non-alcoholic steatohepa-
titis (NASH)-related cirrhosis and 60 age- and sex-
matched controls with cirrhosis of other aetiologies
who underwent liver transplantation. The two groups
were compared regarding the prevalence of CAD and
that of risk factors for atherosclerosis. The prevalence
of CAD was found to be higher in NASH-cirrhosis than
in cirrhosis due to other aetiologies (21.6% vs. 3.3%,
p < 0.05). Also, patients with NASH-cirrhosis were
found to have higher prevalence of arterial hypertension
(51.6% vs. 20%), diabetes mellitus (65% vs. 31.6%),
obesity (28.3% vs. 6.6%), and the metabolic syndrome
(48.3% vs. 10%) compared to those with cirrhosis of
other aetiologies (p < 0.05 for all). The two groups did
not diﬀer signiﬁcantly in smoking habits or the presence
of atherosclerosis in hepatic arteries of explanted livers
[1]. The authors concluded that CAD and major risk
factors for atherosclerosis are signiﬁcantly more preva-
lent in subjects with NASH-cirrhosis compared to cir-
rhosis of other aetiologies.
The prevalence of CAD has been considered to be
low among patients with liver cirrhosis compared to
the general population. This notion is based mainly on
autopsy studies since the 1960s and 1970s [2,3] as well
as on studies from the South of Europe in which the
majority of included patients had cirrhosis due to hepa-
titis C [4,5]. Although no formal comparison with a con-
trol population was performed, the study of Kadayifci
et al. suggests that patients with NASH-cirrhosis do
not have a low prevalence of CAD. However, the most
common cause of cirrhosis in Western countries is alco-
holic liver disease (ALD) and, unfortunately, no patients
with ALD-cirrhosis were included in the study by Kad-
ayifci et al. [1]. Comparative data on the prevalence of
CAD and its risk factors in patients with cirrhosis of dif-
ferent aetiologies are largely lacking.
We recently conducted a prospective study on the
prevalence of CAD and its risk factors in 127 consecu-
tive patients with liver cirrhosis compared to a sample
of subjects from the general population (n = 203) [6].
A total of 55/127 patients (43%) had ALD-cirrhosis,
22 (17%) had NASH (or cryptogenic) cirrhosis, and 50
(40%) had cirrhosis of other aetiologies. CAD was
found to be more common in cirrhotic patients com-
pared to controls (20% vs. 12%, p = 0.001). In regression
analysis, CAD was independently related to diabetes
(odds ratio (OR) 5.47, 95% conﬁdence interval (CI)
2.44–12.28), but not to liver cirrhosis. In the liver cirrho-
sis group only ALD-cirrhosis (OR 9.5, 95% CI 1.08–
83.4) and age (OR 1.23 per year, 95% CI 1.06–1.43) were
independently related to CAD [2]. In this study,
although ALD-cirrhosis was more common among cir-
rhotic patients with CAD than in those without CAD
(65% vs. 38%, p = 0.01), the prevalence of NASH-cir-
rhosis did not diﬀer signiﬁcantly between the two groups
(23% vs. 16%, p > 0.05) and, thus, the latter was not en-
tered in the regression analysis [6].
We have now stratiﬁed our cohort according to etiol-
ogy of liver cirrhosis, thus dividing it into three groups:
the ALD-cirrhosis group (n = 55), the NASH-cirrhosis
group (n = 22), and the groups of cirrhosis due to other
aetiologies (n = 50). The prevalence of CAD did not
diﬀer signiﬁcantly between NASH- and ALD-cirrhosis
but was lower in cirrhosis of other aetiologies compared
to both groups (p < 0.05) (Fig. 1). The prevalence of
CAD risk factors is shown in Table 1. Patients with
NASH-cirrhosis were older and had diabetes and his-
tory of arterial hypertension more often than patients
